Avalo Therapeutics adds Ron Philip to its board of directors

Avalo Therapeutics, Inc. (Nasdaq: AVTX) has appointed Ron Philip to its board of directors, the clinical-stage biotechnology company announced in a press release.

Philip brings more than 30 years of biopharmaceutical experience to the role. He currently serves as executive chair of CREATE Medicines. Previously, he served as chief executive officer of Orbital Therapeutics, where he led the company through its $1.5 billion acquisition by Bristol Myers Squibb.

Prior to Orbital Therapeutics, Philip held senior leadership positions at Spark Therapeutics, eventually becoming chief executive officer. In that role, he oversaw the commercial launch of LUXTURNA, an FDA-approved gene therapy, and was involved in Spark's $4.8 billion acquisition by Roche. Earlier in his career, he held leadership roles at Pfizer and Wyeth, supporting products including ENBREL and XELJANZ. He also serves on the boards of Harmony Biosciences and City Therapeutics.

"Ron's strategic and commercial expertise, including his proven success bringing novel therapies to market, will be invaluable as we advance abdakibart in hidradenitis suppurativa into phase 3 and beyond," said Garry Neil, MD, chief executive officer of Avalo Therapeutics.

Avalo is developing abdakibart, an anti-IL-1β monoclonal antibody, as a treatment for hidradenitis suppurativa. The company recently reported positive topline data from a Phase 2 clinical trial of the drug.

You May Also Be Interested In

• Solidion Technology adds three independent directors to its board
• TryHard Holdings regains Nasdaq compliance after reverse stock split
• Array Technologies acquires wire management firm Affordable Wire Management